NeoGenomics, Inc. Reports 42% Test Volume Growth, 26% Revenue Growth and 22% Increase in Adjusted EBITDA for the Third Quarter 2012

Published: Oct 31, 2012

FT. MYERS, Fla., Oct. 31, 2012 /PRNewswire/ -- NeoGenomics, Inc. (NASD OTC QB: NGNM), a leading provider of cancer genetic testing services today reported its results for the third quarter 2012.

Third Quarter 2012 Highlights:
42% Test Volume Growth
26% Revenue Growth
22% Increase in Adjusted EBITDA
Net Loss of ($0.02) per Share Due to Impacts from TC Grandfather Expiration
New California Laboratory Location Opened

Back to news